OnDosis will revolutionize the way we take our medicines through integration with intelligent dosing and health technology to improve patient outcomes across a multitude of diseases.
While pharmaceutical innovation has accelerated, dosing has stayed the same, resulting in a great number of unmet needs. Today, the calls for change are at an all-time high—and our revolution will ensure that dosing catches up with the scientific advances of modern medicine and digital therapeutics.
Our proprietary technology delivers flexible and individual dosing of oral medicines. We provide reassurance in disease management, support adherence and provide greater convenience for patients. Right now, our focus is to develop solutions for diseases that place significant burdens on both patients and healthcare. This includes ADHD, rare diseases, cancer, immunosuppression for organ transplants, Parkinson’s disease and epilepsy. Our mission is to help millions of people worldwide to get a better everyday life, thanks to individualized, correct, adjustable and easy-to-swallow doses.
Our technology is flexible, which makes it ideal for use in disease areas and patient segments where tablets, pills or capsules do not provide a good fit for the patient or the treatment goal.
OnDosis was founded in 2017 and our headquarters are located in Gothenburg, Sweden.
We partner with pharmaceutical companies based on co-development and license agreements. And we make sure that our technology fits the medicine they develop.
We also drive our own formulation development and combine it with the core technology to produce fully developed combination medicines. Our target is areas where the care is currently based on medicines that have lost exclusivity and where there is a great unmet need. Here, we seek commercialization partners.
Our driving force is for our technology to enable faster and better clinical development. This includes novel approaches to dose finding and adaptive trial design. But also the capability to connect clinical results with patient behavior and engagement.
Martin cofounded OnDosis in 2017 based on a concept from AstraZeneca. He has solid experience from senior roles within the pharmaceutical industry across commercial and development at local, regional and global level. Martin has a past as Global lead for the Respiratory franchise in AstraZeneca and as CEO of the AstraZeneca Nordic-Baltic Region.
Jonas has a background within the management consulting industry. In his previous position he spent seven years at EY Advisory Services as project manager, leading strategic projects for clients, for example within healthcare, medtech and pharmacy industry.
Stéphane has 18 years of experience in product development. He has worked for the pharma and medtech industry and has vast experience in development of drug-device combinations and medical devices. Stéphane has held leadership and managerial positions with AstraZeneca.
Stina has worked 15+ years within research, product development and clinical affairs at global implant companies Nobel Biocare and Cochlear. She has significant experience from development of Class I-III medical devices and drug-device combination products. Before joining OnDosis, Stina held a position as Head of Clinical Affairs at Cochlear.
Joshua joined OnDosis in 2021. He has 10+ years of experience from IoT, open innovations, and M&A activities within the Med Tech industry. Joshua specializes in ensuring that scientific breakthroughs are combined with sound business development strategies. He previously held several leading roles within IoT and innovation at Essity.
Staffan has a solid background as an accomplished commercial oriented leader in medical devices. He has worked as EVP Global Commercial and Strategy for Mölnlycke Healthcare and spent nearly 25 years in various positions within Johnson & Johnson including senior positions based in Belgium as well as in Sweden. He is currently also a board member in Ferrosan Medical Devices.
Kay is in his global role at AstraZeneca responsible for partnering and in- and out-licensing of cardiovascular, renal and metabolism assets in early clinical and pre-clinical development. He has almost 20 years of post-doctoral experience of R&D, global alliance management and business development roles at AstraZeneca. He is the author/co-author of 15 research papers and 13 patents.
Klementina leads the University of Gothenburg’s holding company GU Ventures, that operates as an incubator and invests in the commercialization of innovations. She works actively with financing, start-ups and managing companies within the GU Ventures AB sphere. Previous assignments include the business plan competition, Venture Cup, various Volvo companies, Daimler Chrysler and Geveko Industries.
Anders is investment director of the early-stage life science investment company Radforsk, which is focused on immunotherapies and precision medicines. He is an experienced investment and business development professional with broad experience from the life science industry covering management positions, strategy and business development, research collaborations, licensing deals, M&A and IPOs. He holds several chairman and non-executive director positions in Norwegian biotech companies. He holds an MBE degree.
Johan has a solid background consulting in the health care industry globally on strategic, M&A as well as operational topics. He leads BCG’s global Private Equity Practice, advising on investments and value creation in multiple industries but with a focus in health care. He is also a core member of the firm’s Health Care as well as Corporate Development and Global Advantage practices. Johan has been involved in OnDosis from the strategy definition and business plan development.
Adina has a background as MD (leg. läk.) and earned her PhD in clinical epidemiology at the Karolinska Institute. Adina has broad experience from the MedTech and Pharmaceutical industries, as well as Payer and Provider organizations. She previously worked as senior project leader with the Boston Consulting Group, leading life science projects in Europe, US and the Middle East. She currently serves as Strategy Director at Elekta.